Showing 1292 results
- Media Release /Study discontinued due to feasibility of recruitment; no safety issues have been reported or efficacy conclusions made Novartis remains committed to ongoing research and development for COVID-19…
- Media Release /Results from year two of the pivotal Phase III KITE clinical trial reaffirmed visual acuity gains and fluid reduction findings as well as safety profile from year one1,2 In key fluid-related…
- Media Release /In the updated analysis from ELIANA, Kymriah demonstrated an 82% remission rate within 3 months in pediatric patients with r/r ALL; relapse-free survival was 62% at 24 months, with median duration…
- Media Release /Inclisiran, an investigational medicine, showed durable and potent reduction of low-density lipoprotein cholesterol (LDL-C) in patients with atherosclerotic cardiovascular disease (ASCVD), ASCVD risk…
- Media Release /ROSALIA study met primary endpoints, confirming proposed biosimilar denosumab matches reference product in terms of pharmacokinetics, pharmacodynamics, efficacy, safety and immunogenicity in…
- Media Release /Two pivotal Phase III studies did not show additional improvement in best corrected visual acuity (BCVA) for pegpleranib and Lucentis (ranibizumab) combination treatment over standard of care…
- Key Release /Ad hoc announcement pursuant to Art. 53 LR FDA concluded that OAV-101 intrathecal (IT) clinical program may proceed based on data from nonclinical toxicology study New Phase 3 STEER study will…
- Key Release /Ad hoc announcement pursuant to Art. 53 LR Kisqali plus endocrine therapy (ET) significantly reduced the risk of disease recurrence compared to standard ET alone in the adjuvant setting1…
- Media Release /Both ASCLEPIOS I and II studies met their primary endpoints in patients with relapsing forms of MS (RMS)[1]; overall ofatumumab (OMB157), a subcutaneous, potent, fully-human antibody targeting CD20…
- Media Release /Basel, March 28, 2018 - Novartis will present new data from the HAWK and HARRIER Phase III trials at the upcoming Association for Research in Vision and Ophthalmology (ARVO) 2018 Annual Meeting,…
Pagination
- ‹ Previous page
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- …
- 130
- › Next page